Abstract: This disclosure relates to formulations containing arginine and other ingredients useful in managing acute and chronic complications of coronavirus infections, including respiratory symptoms fatigue, hypercoagulable state, cardiac symptoms, conditions that result from endothelial dysfunction, altered T-cell function/immune dysregulation, mitochondrial dysfunction, and/or and other complications often associated with coronavirus or other viral infections.